A Multicentre, Open Label, Phase I Trial in Japan of the MEK Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2018
At a glance
- Drugs Pimasertib (Primary)
- Indications Liver cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Merck KGaA
- 31 Aug 2018 Biomarkers information updated
- 19 Oct 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 19 Apr 2015 Planned End Date changed from 1 Jan 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.